Amphastar Pharmaceuticals, Inc.

DB:29A Stock Report

Market Cap: €2.0b

Amphastar Pharmaceuticals Future Growth

Future criteria checks 3/6

Amphastar Pharmaceuticals is forecast to grow earnings and revenue by 6.7% and 7.8% per annum respectively. EPS is expected to grow by 4.5% per annum. Return on equity is forecast to be 24.8% in 3 years.

Key information

6.7%

Earnings growth rate

4.5%

EPS growth rate

Pharmaceuticals earnings growth21.2%
Revenue growth rate7.8%
Future return on equity24.8%
Analyst coverage

Good

Last updated22 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:29A - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268732092222865
12/31/20258071862022496
12/31/20247381741692226
9/30/2024724158170208N/A
6/30/2024713167178213N/A
3/31/2024676155161198N/A
12/31/2023644138145184N/A
9/30/2023601135140175N/A
6/30/2023541102100131N/A
3/31/2023519935179N/A
12/31/2022499916589N/A
9/30/20224857790114N/A
6/30/2022477917097N/A
3/31/202245581100126N/A
12/31/2021438627198N/A
9/30/2021413364574N/A
6/30/2021384105281N/A
3/31/202136824579N/A
12/31/202035012357N/A
9/30/202033771346N/A
6/30/20203344-1125N/A
3/31/2020327521247N/A
12/31/201932249042N/A
9/30/201932952346N/A
6/30/2019324532773N/A
3/31/20193162-2326N/A
12/31/2018295-6-438N/A
9/30/2018265-7-538N/A
6/30/2018248-9N/A25N/A
3/31/2018242-4N/A25N/A
12/31/20172404N/A39N/A
9/30/20172430N/A43N/A
6/30/20172504N/A42N/A
3/31/20172529N/A47N/A
12/31/201625510N/A39N/A
9/30/201626921N/A28N/A
6/30/201626814N/A30N/A
3/31/20162540N/A23N/A
12/31/2015252-3N/A11N/A
9/30/2015230-13N/A20N/A
6/30/2015226-15N/A30N/A
3/31/2015221-10N/A28N/A
12/31/2014210-11N/A21N/A
9/30/2014209-6N/A17N/A
6/30/2014209-1N/A4N/A
3/31/20142238N/A24N/A
12/31/201323012N/A31N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 29A's forecast earnings growth (6.7% per year) is above the savings rate (1%).

Earnings vs Market: 29A's earnings (6.7% per year) are forecast to grow slower than the German market (21% per year).

High Growth Earnings: 29A's earnings are forecast to grow, but not significantly.

Revenue vs Market: 29A's revenue (7.8% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 29A's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 29A's Return on Equity is forecast to be high in 3 years time (24.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y